On April 21, 2026, major U.S. health insurers expressed significant reservations regarding the Centers for Medicare and Medicaid Services (CMS) Balance program, a new initiative aimed at providing GLP-1 weight-loss medications to Medicare beneficiaries for a flat $50 monthly fee. CVS Health confirmed it will not participate in the voluntary program, while UnitedHealth Group executives highlighted substantial implementation hurdles during an earnings call held earlier today. The program represents a major shift in federal policy regarding obesity treatment, which has historically been excluded from standard Medicare Part D coverage.
The CMS Balance program, scheduled to launch in 2027, is designed to address the high cost of GLP-1 agonists, such as those produced by Eli Lilly and Novo Nordisk. To become fully operational, the program requires participation from insurance plans that collectively cover at least 80% of Medicare Part D beneficiaries. The initiative seeks to leverage federal negotiating power to lower out-of-pocket costs for seniors, many of whom currently face high prices for obesity treatments. CMS officials have framed the program as a vital step in managing chronic conditions associated with weight, such as diabetes and cardiovascular disease.
During a Tuesday morning earnings call, Bobby Hunter, CEO of UnitedHealthcare’s government programs, stated that the company is currently evaluating the program but faces notable challenges and outstanding questions. Hunter noted that the insurer is still working through internal processes and intends to continue a dialogue with CMS officials to clarify how the $50 co-pay model will interact with existing rebate structures. Meanwhile, CVS Health explicitly stated to media outlets that it does not intend to join the program at this time. The refusal of a major carrier like CVS presents a potential obstacle to reaching the 80% participation threshold required by CMS for the program's full implementation.
The resistance from insurers comes as Medicare access remains a critical factor for the long-term growth of the GLP-1 market. With obesity rates among U.S. seniors remaining high, the federal government has faced increasing pressure to expand coverage for weight-loss drugs. However, the financial structure of the Balance program appears to be a point of contention for private insurers who manage Part D plans. These insurers are responsible for the administrative and financial logistics of drug delivery, and many argue that the current proposal does not adequately account for the high list prices of these medications.
While drug manufacturers Eli Lilly and Novo Nordisk have seen increased demand for their respective GLP-1 products, the specifics of the CMS Balance program involve complex rebate and reimbursement structures that insurers claim are difficult to integrate into existing plan designs. CMS has not yet issued a formal response to the statements made by CVS and UnitedHealth, but the agency has previously emphasized that the program is a cornerstone of its strategy to reduce prescription drug costs for the elderly. Industry analysts note that without the participation of the largest private insurers, the program may require significant revisions before its scheduled 2027 start date.